EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comparison of HPV Antibodies Measured Prior to Diagnosis of Anal, Cervical, Oropharyngeal, Penile and Vaginal Cancers in the HPV Cancer Cohort Consortium

Justina Ucheojor Onwuka, Marie-Pierre Nobels, Aimée R Kreimer, Lea Schroeder, Aida Ferreiro-Iglesias, Ilir Agalliu iD, Demetrius Albanes, Qiuyin Cai, Gypsyamber D'Souza, Neal D Freedman, Graham G Giles, Allan Hildesheim iD und 17 weitere

International Journal of Cancer · 30.10.2026

DOI: 10.1002/ijc.70786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 30.10.2026. Verfasst von Justina Ucheojor Onwuka und 28 weiteren Autor:innen. Beteiligte Einrichtung: International Agency for Research on Cancer, Lyon, France. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies against HPV proteins can provide pre‐diagnostic information about cancer development. We described the prevalence of antibodies to proteins of oncogenic HPV types prior to diagnosis of HPV‐related cancers. We analysed pre‐diagnostic blood from 1700 participants with incident HPV‐related cancers (anal = 387, cervical = 274, oropharyngeal = 788, penile = 168, vaginal = 83) and 6221 controls from nine prospective cohorts in Europe, North America and Australia in the HPV Cancer Cohort Consortium. We measured antibodies against E6, E7 and L1 proteins for 6 HPV types, and additionally against E1, E2, E4, E6, E7 and L1 proteins of HPV16 and 18. We described seroprevalence by lead time from blood draw to cancer diagnosis (range: 0–43 years). We found that among oropharyngeal cancers, seroprevalence increased approaching diagnosis for HPV16 E1, E2, E4, E6, E7, L1 and HPV18 E1, E2, L1 (HPV16‐E6: from 10.4% at > 20 years to 35.8% at 0–5 years, vs. 0.3% in controls). Anal cancer showed similar patterns for HPV16 E1, E2, E4, E6 and L1 and HPV18 E2 (HPV16‐E6: from 3.8% at > 20 years to 29.8% at 0–5 years). No trends were observed for cervical, penile, or vaginal cancers. In a multivariable model fit among cases, HPV16‐E6 seropositivity was higher at shorter lead times and more recent calendar periods, lower among US non‐Hispanic Blacks, and varied by cancer type (highest in oropharyngeal followed by anal, vaginal, penile and cervical) (all p < 0.03). In conclusion, pre‐diagnostic HPV antibody responses vary by cancer type, with seroprevalence of 6–9 HPV proteins increasing approaching diagnosis for oropharyngeal and anal cancers, but not cervical, penile or vaginal cancers.

Schlagwörter

Stichwörter der Autor:innen

HPV antibodiesHPV16‐E6HPV‐related cancersbiomarkershuman papillomavirus

Autor:innen und Institutionen

  • International Agency for Research on Cancer, Lyon, France.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Urology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
  • Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Ilir Agalliu, Allan Hildesheim, Wen-Yi Huang, Eivind Ness-Jensen, Nicolas F Schlecht, Hilary A Robbins

Förderung

  • NCI NIH HHS

Zitieren

APA

Onwuka, J. U., Nobels, M. P., Kreimer, A. R., Schroeder, L., Ferreiro-Iglesias, A., Agalliu, I., Albanes, D., Cai, Q., D'Souza, G., Freedman, N. D., Giles, G. G., Hildesheim, A., Huang, W. Y., Hveem, K., Langseth, H., Milne, R. L., Ness-Jensen, E., Schlecht, N. F., Tinker, L. F., …, & Robbins, H. A. (2026). Comparison of HPV Antibodies Measured Prior to Diagnosis of Anal, Cervical, Oropharyngeal, Penile and Vaginal Cancers in the HPV Cancer Cohort Consortium. International Journal of Cancer. https://doi.org/10.1002/ijc.70786

Vancouver

Onwuka JU, Nobels MP, Kreimer AR, Schroeder L, Ferreiro-Iglesias A, Agalliu I, et al. Comparison of HPV Antibodies Measured Prior to Diagnosis of Anal, Cervical, Oropharyngeal, Penile and Vaginal Cancers in the HPV Cancer Cohort Consortium. International Journal of Cancer. 2026. doi:10.1002/ijc.70786

BibTeX
@article{Onwuka2026,
  author = {Onwuka, Justina Ucheojor and Nobels, Marie-Pierre and Kreimer, Aimée R and Schroeder, Lea and Ferreiro-Iglesias, Aida and Agalliu, Ilir and Albanes, Demetrius and Cai, Qiuyin and D'Souza, Gypsyamber and Freedman, Neal D and Giles, Graham G and Hildesheim, Allan and Huang, Wen-Yi and Hveem, Kristian and Langseth, Hilde and Milne, Roger L and Ness-Jensen, Eivind and Schlecht, Nicolas F and Tinker, Lesley F and Ursin, Giske and Visvanathan, Kala and Wassertheil-Smoller, Sylvia and Weinstein, Stephanie J and Zheng, Wei and Nygard, Mari and Johansson, Mattias and Waterboer, Tim and Clifford, Gary M and Robbins, Hilary A},
  title = {Comparison of HPV Antibodies Measured Prior to Diagnosis of Anal, Cervical, Oropharyngeal, Penile and Vaginal Cancers in the HPV Cancer Cohort Consortium},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70786}
}
Kostenlos starten →